210 related articles for article (PubMed ID: 10955784)
21. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
Advani R; Forero-Torres A; Furman RR; Rosenblatt JD; Younes A; Ren H; Harrop K; Whiting N; Drachman JG
J Clin Oncol; 2009 Sep; 27(26):4371-7. PubMed ID: 19636010
[TBL] [Abstract][Full Text] [Related]
22. Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature.
Shin IS; Jang BS; Danthi SN; Xie J; Yu S; Le N; Maeng JS; Hwang IS; Li KC; Carrasquillo JA; Paik CH
Bioconjug Chem; 2007; 18(3):821-8. PubMed ID: 17375899
[TBL] [Abstract][Full Text] [Related]
23. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
24. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.
Tolcher AW; Mita M; Meropol NJ; von Mehren M; Patnaik A; Padavic K; Hill M; Mays T; McCoy T; Fox NL; Halpern W; Corey A; Cohen RB
J Clin Oncol; 2007 Apr; 25(11):1390-5. PubMed ID: 17416859
[TBL] [Abstract][Full Text] [Related]
25. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
26. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
[TBL] [Abstract][Full Text] [Related]
27. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
Bhargava P; Marshall JL; Dahut W; Rizvi N; Trocky N; Williams JI; Hait H; Song S; Holroyd KJ; Hawkins MJ
Clin Cancer Res; 2001 Dec; 7(12):3912-9. PubMed ID: 11751482
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
29. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
[TBL] [Abstract][Full Text] [Related]
31. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
[TBL] [Abstract][Full Text] [Related]
32. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.
Hotte SJ; Hirte HW; Chen EX; Siu LL; Le LH; Corey A; Iacobucci A; MacLean M; Lo L; Fox NL; Oza AM
Clin Cancer Res; 2008 Jun; 14(11):3450-5. PubMed ID: 18519776
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
34. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
35. Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study.
Zhang D; Pier T; McNeel DG; Wilding G; Friedl A
Invest New Drugs; 2007 Feb; 25(1):49-55. PubMed ID: 17001523
[TBL] [Abstract][Full Text] [Related]
36. Hoarseness during treatment with bevacizumab and other vascular endothelial growth factor signalling inhibitors.
Wong H; Yau T; Man CW; Epstein RJ
Acta Oncol; 2009; 48(8):1213-5. PubMed ID: 19863234
[No Abstract] [Full Text] [Related]
37. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
Delbaldo C; Raymond E; Vera K; Hammershaimb L; Kaucic K; Lozahic S; Marty M; Faivre S
Invest New Drugs; 2008 Feb; 26(1):35-43. PubMed ID: 17876527
[TBL] [Abstract][Full Text] [Related]
38. Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (alphavbeta3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits.
Coleman KR; Braden GA; Willingham MC; Sane DC
Circ Res; 1999 Jun; 84(11):1268-76. PubMed ID: 10364564
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma.
Moschos SJ; Sander CA; Wang W; Reppert SL; Drogowski LM; Jukic DM; Rao UN; Athanassiou C; Buzoianu M; Mandic M; Richman L; McKinney L; Leininger J; Tice DA; Hammershaimb L; Kirkwood JM
J Immunother; 2010 Apr; 33(3):316-25. PubMed ID: 20445352
[TBL] [Abstract][Full Text] [Related]
40. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
Agus DB; Gordon MS; Taylor C; Natale RB; Karlan B; Mendelson DS; Press MF; Allison DE; Sliwkowski MX; Lieberman G; Kelsey SM; Fyfe G
J Clin Oncol; 2005 Apr; 23(11):2534-43. PubMed ID: 15699478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
